NCT03934502View on ClinicalTrials.gov

Effect of Meal Composition and Timing on Evobrutinib Bioavailability

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Healthy
Interventions
DRUG

Evobrutinib

Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03934502 - Effect of Meal Composition and Timing on Evobrutinib Bioavailability | Biotech Hunter | Biotech Hunter